Subcutaneous vs intramuscular — does injection site matter for peptides?

A common question in peptide research is whether subcutaneous (under the skin) or intramuscular (into muscle tissue) administration is more appropriate. For the vast majority of research peptides, subcutaneous injection is the standard protocol.

Why subcutaneous is the standard for most peptides:
Subcutaneous administration provides slower, more consistent absorption compared to intramuscular injection. This is generally desirable for peptides that benefit from sustained release rather than a rapid spike. The technique is also more straightforward, uses smaller gauge needles (29-31 gauge insulin syringes), and carries lower risk of hitting nerves or blood vessels.

When intramuscular administration is discussed:
Some research protocols reference intramuscular injection of BPC-157 near a target area, based on the theory that local administration increases concentration at the site. This is debated in the literature — BPC-157 appears to distribute systemically regardless of injection route, though local administration may provide higher initial concentration at the injection site.

There is no strong evidence that intramuscular administration is superior to subcutaneous for any commonly researched peptide.

Injection site rotation in research protocols:
Standard research protocols call for rotating injection sites to prevent lipodystrophy (tissue changes from repeated injection in the same area). Typical rotation patterns documented in the literature include alternating between multiple subcutaneous sites — left and right abdomen, left and right thigh, or the back of the upper arms.

Standard needle specifications for subcutaneous peptide administration:
29-31 gauge, 1/2 inch (12.7mm) needles are standard. Insulin syringes with 1mL capacity are the most commonly used in research protocols. The small gauge minimizes tissue disruption and discomfort.

The research consensus:
Subcutaneous injection with an insulin syringe is the standard protocol for the vast majority of research peptides. Unless published literature for a specific compound recommends a different route, subcutaneous administration is the appropriate default.